Key Takeaway: Imviva Biotech has received FDA Investigational Device Exemption (IDE) authorization for its clonoSEQ® assay, which will be utilized in the TENACITY-01 clinical trial. This assay is designed for highly sensitive next-generation sequencing-based minimal residual disease (MRD) testing, focusing on patients with T-cell malignancies. The trial aims to enhance the identification of eligible patients and accurately assess their treatment responses.
Price reaction · baseline $21.4 (2026-06-29 close) · hit pre-market · clean, no other ADPT news in the window
day 0 close
+0.2%
Market Sentiment Analysis
POSITIVE FACTORS
FDA IDE authorization received for clonoSEQ® assay.
Next-generation sequencing will enhance patient identification.
Trial aims to improve treatment response evaluation.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing
Frequently Asked Questions
What is the purpose of the clonoSEQ® assay?
The clonoSEQ® assay is designed for minimal residual disease (MRD) testing in T-cell malignancies.
What does FDA IDE authorization mean?
FDA IDE authorization allows the use of a medical device in clinical trials to gather safety and effectiveness data.
What is the TENACITY-01 clinical trial?
TENACITY-01 is a clinical trial that aims to evaluate treatment responses in patients with T-cell malignancies.
How will the assay improve patient enrollment?
The assay will identify eligible patients for the trial through highly sensitive MRD testing.